Paclitaxel

点击蓝字 关注我们 编者按 欧洲肿瘤内科学会亚洲年会（ESMO Asia）是亚太地区肿瘤领域极具影响力的多学科学术盛会，聚焦亚洲高发肿瘤特征、区域人群的诊疗差异，同步传递全球前沿肿瘤研究进展，也是展示中国本土肿瘤原创研究成果、促进亚欧肿瘤学界交流的核心国际平台。2026 ESMO Asia定于12月4~6日在新加坡举办。本届大会消化道肿瘤板块亮点纷呈，共有100余项由中国学者牵头/主导的研究成功入选，研究谱系完整覆盖肝癌、胆道肿瘤、胰腺癌、胃癌、食管癌、胃食管肿瘤及结直肠癌等消化道瘤种。本文将系统梳理本次ESMO Asia入选的中国消化道肿瘤相关研究，第一时间速递来自国际舞台的中国原创循证证据，解读前沿发现。 肝癌 Poster&ePoster 海报&电子海报 摘要号：399eTiP 英文标题：Acarbose Combined with Camrelizumab (Cam) Plus Rivoceranib (Rivo) as First-Line Treatment for Hepatocellular Carcinoma (HCC) with Portal Vein Tumor Thrombus (PVTT): A Prospective, Single-Arm, Phase II Clinical Study中文标题：阿卡波糖联合卡瑞利珠单抗（Cam）与阿帕替尼（Rivo）一线治疗伴门静脉癌栓（PVTT）的肝细胞癌（HCC）：一项前瞻性、单臂Ⅱ期临床研究讲者：Tao Han (Shenyang, CN) 摘要号：379eP 英文标题：TKI combined with immunotherapy and interventional therapy for advanced hepatocellular carcinoma with PVTT: a retrospective study中文标题：TKI联合免疫疗法和介入疗法治疗伴有门静脉癌栓的晚期肝细胞癌：一项回顾性研究讲者：Feng Xia (Chongqing, CN) 摘要号：378eP 英文标题：TKI vs Bevacizumab Combined with Immune Checkpoint Inhibitors Plus Interventional Therapy for First-Line Treatment of Advanced HCC with PVTT: A Multi-center Retrospective Study中文标题：TKI对比贝伐珠单抗联合免疫检查点抑制剂及介入治疗用于伴门静脉癌栓晚期肝细胞癌的一线治疗：一项多中心回顾性研究讲者：Changde Guo (Chongqing, CN) 摘要号：377eP 英文标题：Phase II trial of para-toluenesulfonamide (PTS), a novel liquid intratumoral ablative agent, plus TACE in unresectable HCC中文标题：新型瘤内液体消融剂对甲苯磺酰胺（PTS）联合TACE治疗不可切除肝细胞癌的Ⅱ期研究讲者：Tao Hai (Chengdu, CN) 摘要号：376eP 英文标题：Perioperative Adebrelimab Combined With Lenvatinib in Resectable Hepatocellular Carcinoma: A Multicenter Phase II Study中文标题：阿得贝利单抗联合仑伐替尼围手术期治疗可切除肝细胞癌：一项多中心Ⅱ期研究讲者：Guang Tan (Dalian, CN) 摘要号：375eP 英文标题：SERPINE2 Drives Immunotherapy Resistance via Remodeling Tumor Metabolism in Hepatocellular Carcinoma中文标题：SERPINE2通过重塑肝细胞癌的肿瘤代谢驱动免疫治疗耐药性讲者：Wentao Zhao (Hangzhou, CN) 摘要号：374eP 英文标题：GPD1 Restrains AARS1-Dependent Histone Lactylation to Reprogram Glutamine Competition in Hepatocellular Carcinoma中文标题：GPD1抑制AARS1依赖的组蛋白乳酰化，从而重编程肝细胞癌中的谷氨酰胺竞争讲者：Chi Zhang (Hangzhou, CN) 摘要号：373eP 英文标题：The PHPT1–PTPN1–EGFR axis and lenvatinib response in hepatocellular carcinoma中文标题：PHPT1-PTPN1-EGFR信号轴与肝细胞癌仑伐替尼药物应答讲者：Zheng Lei (Hangzhou, CN) 摘要号：371P 英文标题：GMFB Drives Mitochondrial Dysfunction and Promotes MASH Progression via Inhibition of Mitophagy中文标题：GMFB通过抑制线粒体自噬驱动线粒体功能障碍并促进MASH进展讲者：Weilin Wang (Hangzhou, CN) 摘要号：370P 英文标题：First-in-human phase I study of HH-009, an anti-FGF19 monoclonal antibody, in patients with advanced solid tumors中文标题：HH-009（一种抗FGF19单克隆抗体）在晚期实体瘤患者中的首次人体Ⅰ期研究讲者：Jinhui Xue (Guangzhou, CN) 摘要号：332P 英文标题：The activity and safety of icaritin in patients with child pugh ≥8 unresectable hepatocellular carcinoma: A real-world exploratory study中文标题：淫羊藿素用于Child-Pugh评分≥8分的不可切除肝细胞癌患者的疗效与安全性：一项真实世界探索性研究讲者：Dinghu Zhang (Hangzhou, CN) 摘要号：329P 英文标题：Prognostic Value of Binary-CR in Hepatocellular Carcinoma: Post Hoc Analysis of the TALENTACE Study中文标题：二元完全缓解（Binary-CR）在肝细胞癌中的预后价值：TALENTACE研究事后分析讲者：Linan Yin (Harbin, CN) 摘要号：328P 英文标题：Donafenib Combined with HAIC, Icaritin, and Tislelizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): An Open-Label, Single-Arm Exploratory Study中文标题：多纳非尼联合肝动脉灌注化疗、淫羊藿素及替雷利珠单抗一线治疗不可切除肝细胞癌（uHCC）：一项开放标签、单臂探索性研究讲者：Hui Zeng (Hangzhou, CN) 摘要号：327P 英文标题：Comparative Effectiveness and Prognostic Factors of TACE, Targeted‑Immunotherapy, and Their Combination in Hepatocellular Carcinoma Beyond the Up‑to‑7 Criteria: An IPTW‑Adjusted Retrospective Analysis中文标题：经动脉化疗栓塞术（TACE）、靶向免疫疗法及其联合治疗在超出UPTO-7标准的肝细胞癌中的疗效比较及预后因素：一项基于逆概率加权（IPTW）调整的回顾性分析讲者：Xuwei Guo (Shijiazhuang, CN) 摘要号：326P 英文标题：Conversion outcomes following Yttrium-90 radioembolization-based multidisciplinary treatment for hepatocellular carcinoma: a real-world single-center study中文标题：钇-90放射性栓塞治疗肝细胞癌的多学科综合治疗后的转化结果：一项真实世界单中心研究讲者：JUN FU (Fuzhou, CN) 摘要号：323P 英文标题：Transarterial chemoembolisation plus adebrelimab and apatinib for intermediate-to-advanced hepatocellular carcinoma: a multicentre phase II study中文标题：经动脉化疗栓塞联合阿得贝利单抗与阿帕替尼治疗中晚期肝细胞癌：一项多中心Ⅱ期研究讲者：Junming Xu (Zhangzhou, CN) 摘要号：322P 英文标题：Deferred Immunotherapy Following Induction Arterial Chemotherapy for High-risk Unresectable Hepatocellular Carcinoma: A Biomarker-Guided Strategy from a Long-Term Real-World Cohort中文标题：高危不可切除肝细胞癌诱导动脉化疗后延迟免疫治疗：基于长期真实世界队列的生物标志物指导策略讲者：Ming Zhao (Guangzhou, CN) 摘要号：321P 英文标题：Developing a prognostic score for unresectable hepatocellular carcinoma (uHCC) treated with on-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab (TACE+atezo+bev): a post hoc analysis of the TALENTACE trial中文标题：构建按需经动脉化疗栓塞联合阿替利珠单抗+贝伐珠单抗（TACE+atezo+bev）治疗不可切除肝细胞癌（uHCC）的预后评分模型：TALENTACE研究的事后分析讲者：Yonghong Zhang (Beijing, CN) 摘要号：320P 英文标题：FOLFOX-based HAIC plus lenvatinib and cadonilimab for conversion of unresectable hepatocellular carcinoma (HCC): The phase II CCGLC-011 trial中文标题：基于FOLFOX方案的肝动脉灌注化疗联合仑伐替尼与卡度尼利单抗用于不可切除肝细胞癌的转化治疗：Ⅱ期CCGLC-011研究讲者：Han Gao (Wuhan, CN) 摘要号：315P 英文标题：Real-world Adjuvant Treatment Patterns in Chinese Patients with Hepatocellular Carcinoma Following Curative Surgery or Ablation: A Nationwide Physician Survey中文标题：中国肝细胞癌患者根治性手术或消融术后辅助治疗模式的真实世界研究：一项全国性医生调查讲者：Shengyu Huang (Shanghai, CN) 摘要号：314P 英文标题：Neoadjuvant Lenvatinib, Tislelizumab and Hepatic Arterial Infusion Chemotherapy Followed by Adjuvant Tislelizumab for High-Risk Resectable Hepatocellular Carcinoma: A Phase II Trial中文标题：仑伐替尼联合替雷利珠单抗与肝动脉灌注化疗新辅助治疗，序贯替雷利珠单抗辅助治疗高危可切除肝细胞癌：一项Ⅱ期研究讲者：Weihang Lin (Wenzhou, CN) 摘要号：312P 英文标题：Perioperative finotonlimab plus bevacizumab in resectable hepatocellular carcinoma at high risk of recurrence: A prospective, multicenter, single-arm study中文标题：围手术期菲诺利单抗联合贝伐珠单抗治疗复发高风险可切除肝细胞癌：一项前瞻性、多中心、单臂研究讲者：Zhi-Yong Huang (Wuhan, CN) 摘要号：310P 英文标题：M2 macrophage-derived galectin-9 promotes hepatocellular carcinoma progression by enhancing SLC1A5 membrane stability and glutamine metabolismal中文标题：M2巨噬细胞来源的半乳糖凝集素-9通过增强SLC1A5膜稳定性及谷氨酰胺代谢促进肝细胞癌进展讲者：Yujing Guo (Xi'an, CN) 摘要号：309P 英文标题：Dual MET/AXL Inhibition Suppresses Hepatocellular Carcinoma through Tumour Cell–Intrinsic and Microenvironment-Dependent Mechanisms中文标题：MET/AXL双重抑制通过肿瘤细胞内在机制和微环境依赖性机制抑制肝细胞癌讲者：Chenjing Zhu (Nanjing, CN) 摘要号：308P 英文标题：177Lu-KBD881: A Potent and Selective GPC3-Targeting Radiopharmaceutical Drug Conjugate (RDC) for the Treatment of Hepatocellular Carcinoma中文标题：177Lu-KBD881：一种高效且选择性的GPC3靶向放射性药物偶联物（RDC），用于治疗肝细胞癌讲者：Hongzhu Chu (Chengdu, CN) 摘要号：307P 英文标题：The KCNN4-SLC3A2 Axis and Ferroptosis in the Modulation of Lenvatinib Responsiveness in Hepatocellular Carcinoma中文标题：KCNN4-SLC3A2与铁死亡调控肝细胞癌对仑伐替尼的药物应答讲者：Jun Ran Chen (Hangzhou, CN) 摘要号：306P 英文标题：TRAPPC4-Targeting Biomimetic Nanoparticles Restore MHC Class I Antigen Presentation, Reverse Immune Evasion, and Sensitize Hepatocellular Carcinoma to Anti-PD-1 Therapy中文标题：靶向TRAPPC4的仿生纳米颗粒可恢复MHC Ⅰ类抗原呈递，逆转免疫逃逸，并增强肝细胞癌对PD-1抑制剂的敏感性讲者：Sha Yin (Xi'an, CN) 摘要号：305P 英文标题：Association of tertiary lymphoid structure localization and density with prognosis in hepatocellular carcinoma中文标题：三级淋巴结构定位和密度与肝细胞癌预后的关系讲者：Lei-po Lin (Nanning, CN) 摘要号：301P 英文标题：A phospholipid metabolism-based risk signature identifies PCYT1A as a functional regulator of hepatocellular carcinoma progression中文标题：基于磷脂代谢的风险特征表明，PCYT1A是肝细胞癌进展的功能性调节因子讲者：Nan Hu (Beijing, CN) 摘要号：296P 英文标题：Pretreatment emotional distress and immune checkpoint inhibitor efficacy in hepatocellular carcinoma: the SOLACE prospective cohort study中文标题：肝细胞癌患者治疗前情绪困扰与免疫检查点抑制剂疗效的关系：SOLACE前瞻性队列研究讲者：Lin Ye (Guilin, CN) 胆道肿瘤 Poster&ePoster 海报&电子海报 摘要号：388eP 英文标题：First-line dual HER2-targeted therapy plus chemotherapy for patients with HER2-expressing advanced biliary tract cancer: Preliminary results from a prospective study中文标题：一线双重HER2靶向治疗联合化疗治疗HER2表达阳性的晚期胆道癌患者：一项前瞻性研究的初步结果讲者：Yang Ge (Beijing, CN) 摘要号：387eP 英文标题：Prospective multicenter study of first-line inetetamab-based combination therapy for HER2-positive advanced biliary tract cancer中文标题：一项前瞻性多中心研究，评估以伊尼妥单抗为基础的一线联合疗法治疗HER2阳性晚期胆道癌的疗效讲者：Feng Xie (Shenghai, CN) 摘要号：383eP 英文标题：A retrospective study on application of biliary stents in adult liver transplantation中文标题：成人肝移植中胆道支架应用的回顾性研究讲者：Zhongquan Sun (Hangzhou, CN) 摘要号：382eP 英文标题：Selection of Postoperative Adjuvant Therapy Regimens and Efficacy Assessment in Intrahepatic Cholangiocarcinoma中文标题：肝内胆管癌术后辅助治疗方案的选择及疗效评估讲者：Yang Huang (Hangzhou, CN) 摘要号：369P 英文标题：Establishing a Pan-Asia Biliary Tract Cancer Virtual MDT Network: Insights on gaps, priorities, and regional roadmap中文标题：建立泛亚洲胆道癌虚拟多学科团队网络：关于差距、优先事项和区域路线图的见解讲者：Shukui Qin (Nanjing, CN) 摘要号：368P 英文标题：Reducing Regional Disparities in Hepatobiliary Cancer Care Through a Virtual MDT: A Real-World Case from Fuyang, China中文标题：通过虚拟多学科团队减少肝胆肿瘤诊疗中的区域差异：来自中国阜阳的真实案例讲者：Lian-Xin Liu (Hefei, CN) 摘要号：366P 英文标题：Post-acute COVID Monitoring and Timing Assessment of Surgery in Chinese Patients with Hepatobiliary Malignancies and SARS-CoV-2 Infection: A Prospective Observational Study中文标题：中国肝胆恶性肿瘤合并SARS-CoV-2感染患者COVID-19急性期后监测及手术时机评估：一项前瞻性观察研究讲者：Changcheng Tao (Beijing, CN) 摘要号：362P 英文标题：Mapping the nerve-tumour frontier in gallbladder cancer by spatial multi-omics中文标题：利用空间多组学方法绘制胆囊癌神经肿瘤边界图谱讲者：Huisi He (Shanghai, CN) 摘要号：361P 英文标题：Efficacy and Conversion Potential of Gemcitabine-Cisplatin Combined with Immunotherapy and Targeted Therapy in Advanced Biliary Tract Cancer: A Real-World Study中文标题：吉西他滨-顺铂联合免疫疗法和靶向疗法治疗晚期胆道癌的疗效和转化潜力：一项真实世界研究讲者：Lang Chen (Chengdu, CN) 摘要号：360P 英文标题：OLFM4, FGFR1 signalling and neutrophil remodelling in biliary tract cancer中文标题：OLFM4、FGFR1信号通路和中性粒细胞重塑在胆道癌中的作用讲者：Huisi He (Shanghai, CN) 摘要号：357P 英文标题：Hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and pucotenlimab for conversion of initially unresectable intrahepatic cholangiocarcinoma (iCCA): The phase II CCGLC-013 trial中文标题：肝动脉灌注化疗（HAIC）联合仑伐替尼与普特利单抗用于初始不可切除肝内胆管癌（iCCA）的转化治疗：Ⅱ期CCGLC-013研究讲者：Han Gao (Wuhan, CN) 摘要号：353P 英文标题：Composite Biomarker Profiling Identifies Large Duct Type Intrahepatic Cholangiocarcinoma as a Chemotherapy-Responsive Subtype中文标题：复合生物标志物分析鉴定出大导管型肝内胆管癌为化疗敏感亚型讲者：Zhuo Li (Beijing, CN) 摘要号：352P 英文标题：A CXCL10+ Macrophage-Centred Spatial Immune Niche Is Associated With Response to Camrelizumab Plus GEMOX in Unresectable Gallbladder Cancer中文标题：以CXCL10⁺巨噬细胞为核心的空间免疫微环境生态位与不可切除胆囊癌患者卡瑞利珠单抗联合GEMOX方案的治疗应答相关讲者：Wanying Deng (Guangzhou, CN) 摘要号：348P 英文标题：Peripheral nerve infiltration affects the efficacy of neoadjuvant immunotherapy for intrahepatic cholangiocarcinoma中文标题：周围神经浸润影响肝内胆管癌新辅助免疫疗法的疗效讲者：Shu Lizhuang (Shanghai, CN) 摘要号：347P 英文标题：Durvalumab/Pembrolizumab plus Gemcitabine, Cisplatin, and Surufatinib for Advanced Biliary Tract Cancer: A Phase 2 Study中文标题：度伐利尤单抗/帕博利珠单抗联合吉西他滨、顺铂与索凡替尼治疗晚期胆道恶性肿瘤：一项Ⅱ期研究讲者：Miaomiao Gou (Beijing, CN) 摘要号：345P 英文标题：Gemcitabine-based chemotherapy plus PD-1/PD-L1 inhibitors and tyrosine kinase inhibitors for initially unresectable intrahepatic cholangiocarcinoma: A multicenter, retrospective cohort study中文标题：吉西他滨为基础的化疗联合PD-1/PD-L1抑制剂及酪氨酸激酶抑制剂治疗初始不可切除肝内胆管癌：一项多中心回顾性队列研究讲者：Yuan Ding (Hangzhou, CN) 胰腺癌 Poster&ePoster 海报&电子海报 摘要号：396eP 英文标题：Efficacy and safety of splenic artery infusion chemotherapy versus systemic chemotherapy in advanced pancreatic body/tail cancer: a real-world study中文标题：脾动脉灌注化疗与全身化疗治疗晚期胰体尾癌的疗效和安全性：一项真实世界研究讲者：Jianfeng Huang (Guangzhou, CN) 摘要号：343P 英文标题：Efficacy and safety of chemoimmunotherapy in advanced pancreatic cancer中文标题：化疗免疫疗法治疗晚期胰腺癌的疗效和安全性讲者：Hanqi Yu (Hangzhou, CN) 摘要号：342P 英文标题：Personalized mRNA Cancer Vaccine in Pancreatic Cancer: Feasibility, Safety, and Preliminary Biomarker Signals from Real-World Data中文标题：胰腺癌个性化mRNA癌症疫苗：可行性、安全性及来自真实世界数据的初步生物标志物信号讲者：Mantang Qiu (Beijing, CN) 摘要号：341P 英文标题：Neoadjuvant PD-1 Blockade (Toripalimab) Combined with Gemcitabine and Nab-Paclitaxel for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Prospective Interventional Study中文标题：新辅助PD-1阻断（特瑞普利单抗）联合吉西他滨和白蛋白紫杉醇治疗临界可切除和局部晚期胰腺癌：一项前瞻性干预研究讲者：Ziheng Guo (Chengdu, CN) 摘要号：340P 英文标题：Fruquintinib monotherapy as third-line or later treatment for advanced pancreatic ductal adenocarcinoma: Updated results from a multicenter phase II study中文标题：呋喹替尼单药用于晚期胰腺导管腺癌三线及以上治疗：一项多中心Ⅱ期研究更新结果讲者：Jieyun Zhang (Shanghai, CN) 摘要号：338P 英文标题：Synthetic Lethality Targeting IL-1β in KRAS-Mutant Cancer中文标题：针对KRAS突变癌症中IL-1β的合成致死性讲者：Yukai Shan (Hangzhou, CN) 胃癌 Rapid Oral session 快速口头报告 摘要号：1044RO 英文标题：Personalized MRD Monitoring Predicts Recurrence and Guides Tailored Adjuvant Therapy in Post-Neoadjuvant Locally Advanced Gastric Cancer: A Prospective, Multicenter Cohort Study中文标题：个体化MRD监测预测新辅助治疗后局部晚期胃癌复发并指导个体化辅助治疗：一项前瞻性、多中心队列研究讲者：李子禹（北京大学肿瘤医院） Poster&ePoster 海报&电子海报 摘要号：YO30 英文标题：Gastric hepatoid adenocarcinoma achieving pathological complete response after conversion therapy with chemotherapy, trastuzumab, and cadonilimab: a case report中文标题：一例胃肝样腺癌经化疗、曲妥珠单抗和卡度尼利单抗转化治疗后达到病理完全缓解的病例报告讲者：Yarong Li (Taiyuan, CN) 摘要号：1092eP 英文标题：Irinotecan liposome combined with albumin-bound paclitaxel in second-line therapy of advanced gastric cancer: A Single-Arm, Single-Center Clinical Study中文标题：伊立替康脂质体联合白蛋白结合型紫杉醇二线治疗晚期胃癌：一项单臂、单中心临床研究讲者：Rongrong Li (Changsha, CN) 摘要号：1089eP 英文标题：Association between the age-adjusted Charlson Comorbidity Index and postoperative survival in patients with gastric cancer中文标题：年龄校正查尔森合并症指数与胃癌患者术后生存的相关性研究讲者：Yulan Lin (Fuzhou, CN) 摘要号：1086eP 英文标题：Immune-Stromal Characterization of HER2/PD-L1-Defined Subtypes in Gastric Cancer中文标题：胃癌中HER2/PD-L1定义亚型的免疫基质特征分析讲者：Ming-Huang Chen (Taipei City, TW) 摘要号：1076P 英文标题：Multi-Task Deep Learning for Endoscopic Differentiation of Type 1 Grade 1/2 Gastric Neuroendocrine Tumors, Gastric Polyps, and Gastrointestinal Stromal Tumors中文标题：基于多任务深度学习的内镜鉴别诊断：Ⅰ型1/2级胃神经内分泌肿瘤、胃息肉和胃肠道间质瘤讲者：Jiaojiao Hou (Shijiazhuang, CN) 摘要号：1072P 英文标题：Envafolimab Combined with XELOX or SOX as Adjuvant Therapy for Locally Advanced Gastric Cancer: A Prospective, Single-Arm, Exploratory Study中文标题：Envafolimab联合XELOX或SOX方案辅助治疗局部晚期胃癌：一项前瞻性、单臂、探索性研究讲者：Danyu Ma (Wuxi, CN) 摘要号：1055P 英文标题：Peripheral CD8+ T Cell Senescence and Lymphocyte Reduction Emerge at Premalignant Gastric Stages中文标题：外周CD8+ T细胞衰老和淋巴细胞减少出现在胃癌前期阶段讲者：Da-cen Lin (Fuzhou, CN) 摘要号：1054P 英文标题：Single-cell profiling of gastric mucosal remodeling in zolbetuximab-induced gastritis 中文标题：佐妥昔单抗诱导胃炎中胃黏膜重塑的单细胞图谱分析讲者：Miaomiao Gou (Beijing, CN) 摘要号：1053P 英文标题：Baseline clinicogenomic modeling of response groups in gastric cancer treated with immunochemotherapy中文标题：免疫化疗治疗胃癌患者反应组的基线临床基因组学模型讲者：Xin Han (Shijiazhuang, CN) 摘要号：1052P 英文标题：Correlation between Dynamic Changes in Natural Killer Cell Activity, Nutritional Status and Therapeutic Efficacy in Patients with Advanced Gastric Cancer中文标题：晚期胃癌患者自然杀伤细胞活性动态变化、营养状况与治疗效果的相关性研究讲者：Dan Wu (Hefei, CN) 摘要号：1051P 英文标题：The Impact of Delayed Diagnosis and Treatment on Self-Reported Quality of Life in Gastric Cancer Patients: A Prospective Cohort Study中文标题：延迟诊断和治疗对胃癌患者自述生活质量的影响：一项前瞻性队列研究讲者：Xinyu Chen (Fuzhou, CN) 食管癌 Proffered Paper session 优选论文专场 摘要号：1043O 英文标题：Primary Results of Risvutatug Rezetecan (Ris-Rez) in Patients with Advanced Esophageal Squamous-Cell Carcinoma (ESCC): A Phase 2 Clinical Trial中文标题：Risvutatug Rezetecan（Ris-Rez）治疗晚期食管鳞状细胞癌（ESCC）患者的初步结果：一项Ⅱ期临床试验讲者：李宁（河南省肿瘤医院） Poster&ePoster 海报&电子海报 摘要号：1065P 英文标题：Camrelizumab plus paclitaxel and nedaplatin conversion therapy in ESCC: A single-arm phase II trial with retrospective biomarker analysis of combined CUL4A and HSP90β for survival prediction中文标题：卡瑞利珠单抗联合紫杉醇和奈达铂治疗ESCC：一项单臂Ⅱ期临床试验，回顾性分析CUL4A和HSP90β联合生物标志物对生存预测的价值讲者：Jinhong Zhu (Harbin, CN) 摘要号：1064P 英文标题：The Efficacy and Safety of Cetuximab β plus Tislelizumab and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CTC-LAESCC): single-arm, phase II study中文标题：西妥昔单抗β联合替雷利珠单抗及放化疗治疗局部晚期食管鳞癌：CTC-LAESCC单臂Ⅱ期研究讲者：Xiuyong Liao (Chongqing, CN) 摘要号：1063P 英文标题：Adebrelimab plus albumin-paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced resectable esophageal squamous cell carcinoma: a multicenter, single-arm, phase II study中文标题：阿得贝利单抗联合白蛋白紫杉醇与奈达铂用于可切除局部晚期食管鳞癌的新辅助治疗：一项多中心、单臂Ⅱ期研究讲者：Jianqun Ma (Harbin, CN) 摘要号：1060P 英文标题：Survival Outcomes and Ultrasound Radiomics Prognostication in Cervical Lymph Node Oligometastasis Post-Esophagectomy: A Multicenter Retrospective Study Comparing Surgical and Non-Surgical Approaches中文标题：食管切除术后颈部淋巴结寡转移的生存结局与超声组学预后预测：一项对比手术与非手术治疗方案的多中心回顾性研究讲者：Junying Chen (Guangzhou, CN) 摘要号：1059P 英文标题：Preliminary results for a phase II study of sintilimab combined with chemotherapy followed by concurrent chemoradiotherapy as conversion therapy for unresectable locally advanced esophageal squamous cell carcinoma (NICE-CS trial)中文标题：信迪利单抗联合化疗序贯同步放化疗作为不可切除局部晚期食管鳞癌转化治疗的Ⅱ期研究初步结果（NICE-CS研究）讲者：Yuxi Yi (Shanghai, CN) 摘要号：1058P 英文标题：Anlotinib plus Toripalimab with Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II Trial中文标题：安罗替尼联合特瑞普利单抗序贯新辅助放化疗治疗局部晚期食管鳞癌：一项Ⅱ期临床试验讲者：Qiwei Yao (Fuzhou, CN) 摘要号：1056P 英文标题：Development and validation of a clinical decision score to guide adjuvant therapy in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy中文标题：开发和验证临床决策评分，以指导新辅助免疫化疗后食管鳞状细胞癌的辅助治疗讲者：Haiping Jiang (Hangzhou, CN) 摘要号：1049P 英文标题：A Multicenter, Real-world Study on Impact of Smoking on Clinical Outcomes and the Tumor Immune Microenvironment in Metastatic ESCC Patients Receiving First-Line PD-1 Inhibitors: A Role for CD8+ TIL Infiltration中文标题：一项多中心、真实世界研究评估吸烟对接受一线PD-1抑制剂治疗的转移性食管鳞状细胞癌（ESCC）患者的临床结局和肿瘤免疫微环境的影响：CD8+肿瘤浸润淋巴细胞浸润的作用讲者：Fan Dong (Guangzhou, CN) 胃食管肿瘤 Poster&ePoster 海报&电子海报 摘要号：1096P 英文标题：Fruquintinib combined with cadonilimab and nab-paclitaxel as second‑line treatment for advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)中文标题：呋喹替尼联合卡度尼利单抗和白蛋白紫杉醇作为晚期胃或胃食管交界处腺癌（GC/GEJC）的二线治疗讲者：Jieyun Zhang (Shanghai, CN) 摘要号：1068P 英文标题：Long-term survival follow-up of camrelizumab plus Nab-POF conversion therapy in initially unresectable locally advanced or limited metastatic gastric or gastroesophageal junction adenocarcinoma: FDZL-GC001中文标题：卡瑞利珠单抗联合Nab-POF转化疗法治疗初始不可切除的局部晚期或局限性转移性胃癌或胃食管交界处腺癌的长期生存随访：FDZL-GC001讲者：Wanjing Feng (Shanghai, CN) 摘要号：1067P 英文标题：Biomarker-Driven Assessment of Immunochemotherapy with or without Fruquintinib as First-Line Treatment for Advanced Gastric/GEJ Adenocarcinoma: Initial Clinical Results and Subgroup Analysis from the MGC-FLORA Study中文标题：基于生物标志物的免疫化疗联合或不联合呋喹替尼作为晚期胃/GEJ腺癌一线治疗的评估：MGC-FLORA研究的初步临床结果和亚组分析讲者：Chenchen Wang (Shanghai, CN) 摘要号：1066P 英文标题：HCB101 with ramucirumab and paclitaxel as a CD47–SIRPα innate immune combination strategy in previously treated advanced gastric/GEJ cancer中文标题：HCB101联合雷莫芦单抗和紫杉醇作为CD47-SIRPα先天免疫联合策略，用于治疗既往接受过治疗的晚期胃/GEJ癌讲者：Fangling Ning (Yantai, CN) 结直肠癌 Proffered Paper session 优选论文专场 摘要号：152O 英文标题：Regorafenib Combined with Trifluridine/Tipiracil versus Regorafenib Monotherapy in Refractory Metastatic Colorectal Cancer (FDZL-REGOT): A Randomized Phase II Trial中文标题：瑞戈非尼联合曲氟尿苷/替匹嘧啶对比瑞戈非尼单药治疗难治性转移性结直肠癌（FDZL-REGOT）：一项随机Ⅱ期试验讲者：李文桦（复旦大学附属肿瘤医院） Rapid Oral session 快速口头报告 摘要号：154RO 英文标题：Amivantamab monotherapy or in combination with chemotherapy in RAS/BRAF wildtype metastatic colorectal cancer: Asian subset analysis from the phase 1b/2 OrigAMI-1 study中文标题：埃万妥单抗单药或联合化疗治疗RAS/BRAF野生型转移性结直肠癌：Ⅰb/Ⅱ期OrigAMI-1研究的亚洲亚组分析讲者：袁瑛（浙江大学医学院附属第二医院） 摘要号：155RO 英文标题：Single-cell transcriptomic atlas reveals myeloid reprogramming and persistent clonal T-cell expansion underlying pathological complete response to split-course hypofractionated chemoradioimmunotherapy in pMMR/MSS locally advanced rectal cancer中文标题：单细胞转录组图谱揭示pMMR/MSS局部晚期直肠癌分段大分割放化疗联合免疫治疗病理完全缓解的髓系重编程与持续性克隆性T细胞扩增机制讲者：郑榕（ 福建医科大学附属协和医院） 摘要号：1046RO 英文标题：SYS6010 combined with SYH2051 in advanced solid tumors: results from a phase Ib中文标题：SYS6010联合SYH2051治疗晚期实体瘤：一项Ⅰb期研究结果讲者：林榕波（福建省肿瘤医院） 摘要号：1047RO 英文标题：Safety and feasibility of CLDN18.2-specific CAR-NK cells in advanced gastrointestinal cancers: A phase 1 trial中文标题：CLDN18.2特异性CAR-NK细胞治疗晚期消化道肿瘤的安全性与可行性：一项Ⅰ期试验讲者：杨柳（浙江省人民医院） Poster&ePoster 海报&电子海报 摘要号：235eP 英文标题：Oxaliplatin-associated affective toxicity in colorectal cancer is mediated by the IDO1-kynurenine-gut microbiota-ACC neuroimmune axis中文标题：IDO1-犬尿氨酸-肠道菌群-前扣带回皮层神经免疫轴介导结直肠癌中奥沙利铂相关情感毒性讲者：Zhijun Mao (Xian, CN) 摘要号：234eP 英文标题：Trajectories and risk stratification of patient-reported affective toxicity during colorectal cancer chemotherapy: a real-world longitudinal study中文标题：结直肠癌化疗期间患者报告的情感毒性轨迹和风险分层：一项真实世界纵向研究讲者：Yuming Zhang (Xi'an, CN) 摘要号：226eP 英文标题：KBD166: A Novel Neurotensin Receptor 1 (NTSR1) Ligand for Solid Tumor Therapy中文标题：KBD166：用于实体瘤治疗的新型神经降压素受体1（NTSR1）配体讲者：Jing Zhang (Chengdu, CN) 摘要号：224eP 英文标题：Vitamin E plus fruquintinib and tislelizumab in refractory microsatellite-stable metastatic colorectal cancer: interim results of the phase II VENTIF study中文标题：维生素E联合呋喹替尼与替雷利珠单抗治疗难治性微卫星稳定转移性结直肠癌：Ⅱ期VENTIF研究中期结果讲者：Dawei Li (Shanghai, CN) 摘要号：218eP 英文标题： Safety and Feasibility of Preserving the Left Colic Artery and Clearing No.253 Lymph Nodes via Caudal Triangular Region Dissection in LRRRC for Rectal Cancer中文标题：低位局部进展期直肠癌经尾侧三角区清扫保留左结肠动脉并清扫253组淋巴结的安全性与可行性讲者：Pengxing Li (Nanping, CN) 摘要号：201P 英文标题：Fruquintinib Monotherapy Versus Fruquintinib Combined with Chemotherapy in Patients with Refractory Metastatic Colorectal Cancer: A Real-World Retrospective Cohort Study中文标题：呋喹替尼单药对比呋喹替尼联合化疗用于难治性转移性结直肠癌患者：一项真实世界回顾性队列研究讲者：Jen Pei Huang (Taipei City, TW) 摘要号：198P 英文标题：Propensity Score Matching Multicenter Study of Maintenance Strategies versus Drug-free Treatment Break After First-line Systemic Therapy for Metastatic Colorectal Cancer - The Retrospective TRACC Registry中文标题：转移性结直肠癌一线系统治疗后维持治疗策略对比停药治疗间歇的疗效：一项基于TRACC回顾性登记库的多中心倾向性评分匹配研究讲者：Kin Tsun Lee (Hong Kong, HK) 摘要号：197P 英文标题：Antibiotic Exposure Prior to Radiotherapy and Survival Outcomes in Colorectal Cancer: A Propensity Score-Matched Real-World Analysis Using the TriNetX Global Network中文标题：结直肠癌患者放疗前抗生素暴露与生存结局：基于TriNetX全球数据库的倾向性评分匹配真实世界分析讲者：Tisha Lazuana (Taipei City, TW) 摘要号：195P 英文标题：BETTER Trial: The Efficacy and Safety of Bevacizumab Combined with Trifluridine/Tipiracil, Stereotactic Body Radiotherapy, and Tislelizumab in Patients with Microsatellite-Stable Metastatic Colorectal Cancer Receiving Third-Line Therapy中文标题：BETTER研究：贝伐珠单抗联合曲氟尿苷替匹嘧啶、立体定向体部放疗及替雷利珠单抗三线治疗微卫星稳定转移性结直肠癌的疗效与安全性讲者：Qun Zhang (Nanjing, CN) 摘要号：194P 英文标题：UGT1A1 genotype-guided Irinotecan liposome combined with 5-FU/LV+ bevacizumab as first-line therapy in metastatic colorectal cancer：multicenter, phase II clinical study中文标题：基于UGT1A1基因型指导的脂质体伊立替康联合5-FU/LV及贝伐珠单抗一线治疗转移性结直肠癌：一项多中心Ⅱ期临床研究讲者：Yuwen Zhou (Chengdu, CN) 摘要号：193P 英文标题：Precemtabart tocentecan (Precem-TcT) in Chinese patients with metastatic colorectal cancer (mCRC): results from the PROCEADE®-CRC-02 study中文标题：Precemtabart tocentecan (Precem-TcT) 治疗中国转移性结直肠癌 (mCRC) 患者：PROCEADE®-CRC-02研究结果讲者：Yanhong Deng (Guangzhou, CN) 摘要号：192P 英文标题：Sintilimab plus bevacizumab and CapeOx as first-line treatment in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer patients: Updated survival results and biomarker analyses of the BBCAPX-II study中文标题：信迪利单抗联合贝伐珠单抗与CapeOx方案一线治疗RAS突变、微卫星稳定、不可切除转移性结直肠癌：BBCAPX-Ⅱ研究更新生存结果及生物标志物分析讲者：Ning Zhu (Hangzhou, CN) 摘要号：190P 英文标题：Final analysis of CAPability-01: A phase Il trial of combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer中文标题：CAPability-01研究最终分析：抗PD-1联合HDAC抑制剂与抗血管内皮生长因子药物治疗 MSS/pMMR结直肠癌的Ⅱ期研究讲者：Yu-Kun Chen (Guangzhou, CN) 摘要号：188P 英文标题：Metastasectomy, hepatic resection margin status, and survival with first-line panitumumab or cetuximab in RAS wild-type metastatic colorectal cancer: a Taiwanese multicenter cohort中文标题：RAS野生型转移性结直肠癌一线使用帕尼单抗或西妥昔单抗治疗时，转移灶切除术、肝切除切缘状态与生存的相关性：一项中国台湾多中心队列研究讲者：Hung-Chih Hsu (Taoyuan City, TW) 摘要号：186P 英文标题：Postoperative intraperitoneal raltitrexed after cytoreductive surgery for colorectal peritoneal metastases: a single-centre, open-label, phase 1b dose-escalation study中文标题：结直肠癌腹膜转移肿瘤减灭术后行术后腹腔内雷替曲塞给药：一项单中心、开放标签、Ⅰb期剂量递增研究讲者：Guoxiang Cai (Shanghai, CN) 摘要号：184P 英文标题：Peritumoral multimodal radiomics predicts CRLM recurrence中文标题：肿瘤周围多模态放射组学预测CRLM复发讲者：Yanzong Lin (Xiamen, CN) 摘要号：183P 英文标题：Time-Varying Relapse Risk and Surveillance Intensity After Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastases中文标题：初始无法切除的结直肠癌肝转移患者行转化性肝切除术后，复发风险随时间变化及监测强度讲者：Yijiao Chen (Shanghai, CN) 摘要号：180P 英文标题：CT–MRI Multimodal Imaging-based Characterization of Indeterminate Pulmonary Nodules in Rectal Cancer中文标题：基于CT-MRI多模态成像的直肠癌肺部不确定结节的特征分析讲者：Liao Yijun (Guangzhou, CN) 摘要号：178P 英文标题：Neoadjuvant fruquintinib plus tislelizumab and mCapeOX for pMMR/MSS locally advanced rectal cancer: Safety lead-in results of a prospective, randomized, multicenter trial中文标题：新辅助呋喹替尼联合替雷利珠单抗和mCapeOX方案治疗pMMR/MSS局部晚期直肠癌：一项前瞻性、随机、多中心试验的安全性导入结果讲者：Xiaokang Lei (Beijing, CN) 摘要号：171P 英文标题：Tissue-specific mapping of genetic susceptibility in colorectal cancer identifies epithelial and endothelial driver genes and validates the association between WDR74 and oxaliplatin chemoresistance中文标题：结直肠癌遗传易感性的组织特异性定位鉴定出上皮和内皮驱动基因，并验证了WDR74与奥沙利铂化疗耐药性之间的关联讲者：Tingyao Liu (Zhuhai, CN) 摘要号：168P 英文标题：NAMPT-driven NAD⁺ metabolism orchestrates a tumor stiffness–immune axis that mediates immunotherapy resistance in MSS colorectal cancer中文标题：NAMPT驱动的NAD⁺代谢调控肿瘤硬度-免疫轴，从而介导MSS型结直肠癌的免疫治疗耐药性讲者：Chenyang Ye (Hangzhou, CN) 摘要号：165P 英文标题：Preclinical and first-in-human evaluation of [68Ga]NODAGA-SNA009 for PET imaging of GPA33 expression in colorectal cancer中文标题：[68Ga]NODAGA-SNA009 用于PET成像检测结直肠癌中GPA33表达的临床前和首次人体评估讲者：Dong Dai (Tianjin, CN) 摘要号：164P 英文标题：Attention-enhanced digital pathology for MSI prediction in colorectal cancer中文标题：注意力增强型数字病理学在结直肠癌MSI预测中的应用讲者：Yunxia Huang (Xiamen, CN) 摘要号：156P 英文标题：Smoking promotes colorectal cancer risk mediated by type 2 diabetes: a Mendelian randomization study中文标题：吸烟通过2型糖尿病介导增加结直肠癌风险：一项孟德尔随机化研究讲者：Yu Zhou (Fuzhou, CN) （来源：肿瘤瞭望消化时讯） 声 明 凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。